CDK6 Inhibition: A Novel Approach in AML Management
Acute myeloid leukemia (AML) is a complex disease with an aggressive clinical course and high mortality rate. The standard of care for patients has only changed minimally over the past 40 years. However, potentially useful agents have moved from bench to bedside with the potential to revolutionize t...
Main Authors: | Iris Z. Uras, Veronika Sexl, Karoline Kollmann |
---|---|
Format: | Article |
Language: | English |
Published: |
MDPI AG
2020-04-01
|
Series: | International Journal of Molecular Sciences |
Subjects: | |
Online Access: | https://www.mdpi.com/1422-0067/21/7/2528 |
Similar Items
-
Therapeutic Vulnerabilities in <i>FLT3</i>-Mutant AML Unmasked by Palbociclib
by: Iris Z. Uras, et al.
Published: (2018-12-01) -
CDK4/6 and MAPK—Crosstalk as Opportunity for Cancer Treatment
by: Lisa Scheiblecker, et al.
Published: (2020-11-01) -
Modeling and Analysis of Acute Leukemia using Human Hematopoietic Stem and Progenitor Cells
by: Lin, Shan
Published: (2016) -
RUNX1-ETO: Attacking the Epigenome for Genomic Instable Leukemia
by: Emiel van der Kouwe, et al.
Published: (2019-01-01) -
CDK4/6 Inhibitors in Melanoma: A Comprehensive Review
by: Mattia Garutti, et al.
Published: (2021-05-01)